AbbVie Partners With Valkai to Embed AI Across Targeted Areas of Clinical Development
核心洞察
AbbVie has entered a partnership with life sciences AI platform Valkai (搜索) to strengthen integrated artificial intelligence capabilities across targeted areas of clinical development.
The collaboration is intended to help AbbVie teams generate insights faster and support opportunities to reduce drug development timelines.
AbbVie executives said AI can cut time spent on manual processes so clinical teams focus more on scientific interpretation and clinical strategy.
AbbVie is investing in its artificial intelligence infrastructure through a new partnership with Valkai (搜索), a life sciences AI platform, to strengthen integrated AI capabilities across clinical development. The North Chicago-based company announced the collaboration on Sept. 29, 2026.
Under the partnership, AbbVie will deploy purpose-built AI capabilities designed to improve efficiency across targeted areas of clinical research, help teams generate insights more quickly and support opportunities to reduce development timelines. The company said the collaboration builds on its existing foundation of applying AI across research and development, and is intended to further scale data-driven insights and innovation across the organization.
Executive Rationale
Nicholas Donoghoe, executive vice president and chief business and strategy officer at AbbVie, framed the partnership around the growing complexity of clinical data.
"At AbbVie, we are focused on applying AI where it can create meaningful impact for our business and, ultimately, for patients," Donoghoe said. "As clinical data continues to grow in volume and complexity, partnerships like Valkai (搜索) help us generate insights faster and enable our teams to spend more time on the decisions that matter most. By combining advanced AI capabilities with human expertise, we can help bring new medicines to patients more efficiently."
Andrew Campbell, M.D., vice president of clinical sciences at AbbVie, said the clinical sciences function depends on the ability to learn quickly, adapt intelligently and make confident decisions based on an ever-growing body of evidence.
"AI capabilities, like Valkai (搜索), have the potential to help us reduce time spent on manual processes and focus more attention on scientific interpretation and clinical strategy, and ultimately, the insights that can advance medicines for patients," Campbell said.
Vignesh Rajendran, co-founder and chief executive officer of Valkai (搜索), said the two organizations would combine advanced AI capabilities with deep scientific expertise. "AbbVie's scale, innovation and unwavering focus on patients make this the kind of partnership that can turn bold ambition into meaningful impact," he said.
Governance and Platform
AbbVie said AI serves as a critical tool across the company to complement employee insight, enabling teams to drive strategic priorities and expedite delivery of medicines to patients, while maintaining a commitment to responsible and ethical use. The company's enterprise approach, AI@AbbVie, is described as embedding AI across R&D, operations and other core business functions, guided by human expertise and responsible governance.
Valkai (搜索) describes itself as the AI operating system for life sciences, with a stated mission to significantly accelerate time to market for critical medicines. The company said global Fortune 500 pharmaceutical and medtech leaders partner with it to enable faster, smarter decision-making, and that its team includes staff from OpenAI, Google DeepMind, Sierra and Glean.
AbbVie's stated therapeutic focus areas include immunology, neuroscience and oncology, along with products and services in its Allergan Aesthetics portfolio. The company did not disclose financial terms of the partnership or specify which clinical programs will use the Valkai (搜索) platform.